
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#04ATA1695_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kr1695_exhibit_99.1"> </A>
<A NAME="toc_kr1695_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;99.1    <BR>    </B></FONT></P>

<P><FONT SIZE=2><B>
<IMG SRC="g832257.jpg" ALT="GRAPHIC" WIDTH="94" HEIGHT="93">
  </B></FONT></P>

<P><FONT SIZE=4><B>N E W S  </B></FONT></P>

<P><FONT SIZE=2><B>FOR IMMEDIATE RELEASE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="77%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="10%"><FONT SIZE=2>Contact:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2>Bud Ingalls / Craig Brown<BR>
VP-Finance &amp; Chief Financial Officer / Director, Finance<BR>
(678)&nbsp;728-2115 / (678)&nbsp;728-2117</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2><B>SEROLOGICALS ANNOUNCES CLOSING OF PUBLIC OFFERING<BR>
Underwriters Exercise Over-Allotment Option  </B></FONT></P>

<P><FONT SIZE=2><B>ATLANTA, GA&#151;December&nbsp;21, 2004&#151;</B></FONT><FONT SIZE=2>Serologicals Corporation (NASDAQ:SERO) announced today the closing of its previously
announced public offering of 4,830,000 shares of its Common Stock at a price of $22.80 per share. The Company obtained net proceeds, after deduction of underwriting discounts and commissions but
before expenses, of $105.16&nbsp;million from the offering. David A. Dodd, President and Chief Executive Officer of Serologicals, stated "We are very pleased at the reception of our offering. Demand
for our shares was significant, leading the underwriters to exercise their entire over-allotment option of 630,000 shares. Serologicals received approximately $13.7&nbsp;million of
additional net proceeds as a result of the exercise of the over-allotment option. After using approximately $80&nbsp;million to repay our term indebtedness, we will have additional
resources to continue to pursue our strategic growth strategy." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J.P.
Morgan Securities&nbsp;Inc. served as the sole bookrunning manager for the offering. Banc of America Securities LLC and Pacific Growth Equities, LLC were co-managers.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such state. A registration statement relating to these securities has been filed with and declared effective
by the Securities and Exchange Commission. Copies of the prospectus relating to the offering may be obtained from the offices of J.P. Morgan Securities,&nbsp;Inc., Chase Distribution&nbsp;&amp;
Support Service, 1 Chase Manhattan Plaza, Floor 5B, New York, NY 10081. </FONT></P>

<P><FONT SIZE=2><B>About Serologicals Corporation  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products, enabling technologies and services to a diverse customer
base that includes major life science companies and leading research institutions. Our customers use our products, technologies and services in a wide variety of their activities, including basic
research, drug discovery, diagnosis and biomanufacturing. Our products, technologies and services are essential tools for research in key disciplines, including neurology, oncology, hematology,
immunology, cardiology, proteomics, infectious diseases, cell signaling and molecular biology. In addition, the Company is the world's leading provider of monoclonal antibodies for the blood typing
industry. Serologicals has more than 1,000 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
statement in this release regarding the use of the net proceeds of our offering of shares of our Common Stock to implement our strategic growth strategy is a forward-looking
statement within the
meaning of the Private Securities Litigation Reform Act of 1995. Information concerning certain risks and uncertainties related to our implementation of our strategic growth strategy is set forth in
the prospectuses related to the offering. You should not place undue reliance on this forward-looking statement, since the statement speaks only as of the date it is made and the Company undertakes no
obligation to publicly update such statement based on events that may occur after the date of this press release. Serologicals is a registered trademark of Serologicals Royalty Company. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serologicals
is a registered trademark of Serologicals Royalty Company. </FONT></P>

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="6",CHK=382088,FOLIO='blank',FILE='DISK013:[04ATA5.04ATA1695]KR1695A.;5',USER='SSTANSE',CD='23-DEC-2004;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="04ATA1695_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kr1695_1">Exhibit 99.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTANSE,SEQ=,EFW="2149161",CP="SEROLOGICALS CORPORATION",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

